Stryker Co. (NYSE:SYK) Position Trimmed by Ledyard National Bank

Ledyard National Bank cut its stake in shares of Stryker Co. (NYSE:SYK) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,746 shares of the medical technology company’s stock after selling 126 shares during the quarter. Ledyard National Bank’s holdings in Stryker were worth $629,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. GHP Investment Advisors Inc. increased its stake in Stryker by 0.8% in the 4th quarter. GHP Investment Advisors Inc. now owns 37,618 shares of the medical technology company’s stock worth $13,545,000 after purchasing an additional 305 shares in the last quarter. Oakworth Capital Inc. increased its position in shares of Stryker by 3.9% in the fourth quarter. Oakworth Capital Inc. now owns 6,104 shares of the medical technology company’s stock worth $2,198,000 after acquiring an additional 230 shares in the last quarter. Silver Oak Securities Incorporated acquired a new stake in shares of Stryker during the fourth quarter valued at approximately $571,000. Adero Partners LLC lifted its position in shares of Stryker by 5.4% in the 4th quarter. Adero Partners LLC now owns 801 shares of the medical technology company’s stock valued at $288,000 after acquiring an additional 41 shares in the last quarter. Finally, YANKCOM Partnership acquired a new position in Stryker in the 4th quarter worth approximately $139,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Down 0.7 %

Shares of SYK stock opened at $396.24 on Friday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a market cap of $151.06 billion, a PE ratio of 51.06, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $377.08 and its two-hundred day moving average is $364.24.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the firm posted $3.46 EPS. Equities analysts predict that Stryker Co. will post 13.5 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SYK shares. Robert W. Baird boosted their target price on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. UBS Group upped their price target on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group raised their price objective on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Royal Bank of Canada raised their price target on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 5.50% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.